Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free BMEA Stock Alerts

Biomea Fusion (BMEA) Financials

Biomea Fusion logo
$0.87 +0.04 (+4.20%)
As of 11:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Biomea Fusion

Annual Income Statements for Biomea Fusion

This table shows Biomea Fusion's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.20 -5.32 -42 -82 -117 -138 -62
Consolidated Net Income / (Loss)		 -1.20 -5.32 -42 -82 -117 -138 -62
Net Income / (Loss) Continuing Operations		 -1.20 -5.32 -42 -82 -117 -138 -62
Total Pre-Tax Income 		-1.20 -5.32 -42 -82 -117 -138 -62
Total Operating Income		 -1.20 -5.33 -42 -84 -126 -144 -84
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1.20 5.33 42 84 126 144 84
Selling, General & Admin Expense		 0.10 1.66 14 21 24 26 19
Research & Development Expense		 1.09 3.67 28 63 103 118 62
Impairment Charge		 - - - - 0.00 0.00 2.21
Total Other Income / (Expense), net		 0.00 0.00 0.10 1.81 8.88 5.64 22
Interest & Investment Income		 - 0.00 0.10 1.81 8.88 5.64 1.86
Other Income / (Expense), net		 - - - - - - 20
Basic Earnings per Share		 ($0.20) ($0.51) ($1.74) ($2.80) ($3.44) ($3.83) ($1.18)
Weighted Average Basic Shares Outstanding		 6.05M 10.53M 23.86M 29.27M 34.11M 36.11M 52.23M
Diluted Earnings per Share		 ($0.20) ($0.51) ($1.74) ($2.80) ($3.44) ($3.83) ($1.18)
Weighted Average Diluted Shares Outstanding		 6.05M 10.53M 23.86M 29.27M 34.11M 36.11M 52.23M
Weighted Average Basic & Diluted Shares Outstanding		 6.05M 10.53M 23.86M 29.61M 35.89M 37.57M 72.30M

Quarterly Income Statements for Biomea Fusion

This table shows Biomea Fusion's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -12
Consolidated Net Income / (Loss)		 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -12
Net Income / (Loss) Continuing Operations		 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -12
Total Pre-Tax Income 		-35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -12
Total Operating Income		 -37 -41 -39 -34 -30 -30 -21 -21 -12 -13 -13
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 37 41 39 34 30 30 21 21 12 13 13
Selling, General & Admin Expense		 6.46 7.28 7.07 6.80 4.83 6.82 4.71 4.20 3.60 3.65 3.62
Research & Development Expense		 31 34 32 27 25 23 17 14 8.12 9.12 9.14
Other Special Charges / (Income)		 - - - - - 0.00 0.00 - - - 0.00
Total Other Income / (Expense), net		 2.44 2.00 1.62 1.25 0.77 0.45 0.31 4.40 16 0.43 0.32
Interest & Investment Income		 2.44 2.00 1.62 1.25 0.77 0.45 0.31 4.40 -3.53 0.43 0.32
Basic Earnings per Share		 ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17) ($0.12)
Weighted Average Basic Shares Outstanding		 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M 72.36M
Diluted Earnings per Share		 ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17) ($0.12)
Weighted Average Diluted Shares Outstanding		 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M 72.36M
Weighted Average Basic & Diluted Shares Outstanding		 35.89M 35.94M 36.21M 36.24M 37.57M 37.57M 59.51M 70.70M 72.30M 72.30M 72.48M

Annual Cash Flow Statements for Biomea Fusion

This table details how cash moves in and out of Biomea Fusion's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 61 84 -34 65 -119 -2.47
Net Cash From Operating Activities		 -4.46 -35 -62 -97 -120 -70
Net Cash From Continuing Operating Activities		 -4.46 -35 -62 -97 -120 -70
Net Income / (Loss) Continuing Operations		 -5.32 -42 -82 -117 -138 -62
Consolidated Net Income / (Loss)		 -5.32 -42 -82 -117 -138 -62
Depreciation Expense		 0.01 0.25 0.69 1.52 1.75 1.41
Amortization Expense		 0.00 1.22 0.14 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.45 6.23 11 17 22 -6.29
Changes in Operating Assets and Liabilities, net		 0.41 -1.57 7.67 2.33 -5.15 -3.70
Net Cash From Investing Activities		 -0.05 -33 27 -2.22 -0.36 0.00
Net Cash From Continuing Investing Activities		 -0.05 -33 27 -2.22 -0.36 0.00
Purchase of Property, Plant & Equipment		 -0.05 -3.17 -1.03 -3.37 -0.36 0.00
Sale and/or Maturity of Investments		 0.00 8.31 28 1.15 0.00 0.00
Net Cash From Financing Activities		 66 153 1.24 164 1.67 68
Net Cash From Continuing Financing Activities		 66 153 1.24 164 1.67 68
Issuance of Common Equity		 10 153 1.24 164 1.67 68

Quarterly Cash Flow Statements for Biomea Fusion

This table details how cash moves in and out of Biomea Fusion's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -22 -32 -32 -25 -30 -22 20 -9.58 9.17 -11 -9.87
Net Cash From Operating Activities		 -23 -32 -33 -25 -30 -26 -19 -12 -14 -12 -10
Net Cash From Continuing Operating Activities		 -23 -32 -33 -25 -30 -26 -19 -12 -14 -12 -9.98
Net Income / (Loss) Continuing Operations		 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -8.33
Consolidated Net Income / (Loss)		 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12 -8.33
Depreciation Expense		 0.42 0.42 0.42 0.44 0.47 0.47 0.47 0.43 0.05 0.00 0.07
Non-Cash Adjustments To Reconcile Net Income		 4.57 5.02 6.22 5.46 5.23 3.17 3.90 0.39 -14 1.65 -2.53
Changes in Operating Assets and Liabilities, net		 7.05 0.59 -1.01 1.67 -6.40 -0.81 -2.08 4.04 -4.85 -0.95 0.81
Net Cash From Financing Activities		 0.62 0.12 1.07 0.07 0.41 3.25 40 1.97 23 0.00 0.16
Net Cash From Continuing Financing Activities		 0.62 0.12 1.07 0.07 0.41 3.25 40 1.97 23 0.00 0.16
Issuance of Common Equity		 0.62 0.00 1.19 0.07 0.41 3.26 40 2.60 22 0.00 0.16

Annual Balance Sheets for Biomea Fusion

This table presents Biomea Fusion's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 63 186 129 200 80 59
Total Current Assets		 62 177 118 179 68 58
Cash & Equivalents		 62 146 112 177 58 56
Restricted Cash		 0.00 - 0.35 0.37 0.37 0.00
Prepaid Expenses		 0.53 3.05 4.77 2.32 10 2.24
Plant, Property, & Equipment, net		 0.08 2.97 5.84 5.16 3.77 0.15
Total Noncurrent Assets		 0.22 6.18 5.30 15 7.47 0.37
Long-Term Investments		 0.00 1.88 0.00 - - 0.00
Other Noncurrent Operating Assets		 0.22 4.30 5.30 15 7.47 0.37
Total Liabilities & Shareholders' Equity		 63 186 129 200 80 59
Total Liabilities		 1.62 6.92 21 31 28 29
Total Current Liabilities		 1.62 4.64 19 23 22 11
Accounts Payable		 0.73 1.33 6.83 6.85 13 3.23
Accrued Expenses		 0.63 2.74 12 14 6.66 6.41
Other Current Liabilities		 0.22 0.57 0.62 2.47 2.08 1.46
Total Noncurrent Liabilities		 0.00 2.29 1.67 7.83 6.69 18
Other Noncurrent Operating Liabilities		 0.00 2.29 1.67 7.83 6.69 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.17 179 109 169 52 30
Total Preferred & Common Equity		 5.17 179 109 169 52 30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 5.17 179 109 169 52 30
Common Stock		 13 229 240 418 439 479
Retained Earnings		 -8.18 -50 -132 -249 -387 -449
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.00 - - 0.00

Quarterly Balance Sheets for Biomea Fusion

This table presents Biomea Fusion's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 225 168 136 110 55 73 55 46 37
Total Current Assets		 203 148 116 94 45 65 49 46 36
Cash & Equivalents		 199 145 113 88 36 56 47 45 35
Restricted Cash		 0.37 0.37 0.37 0.37 0.37 - 0.37 0.37 0.37
Prepaid Expenses		 3.41 2.65 3.00 5.65 8.82 8.44 2.80 1.26 1.24
Plant, Property, & Equipment, net		 5.58 4.81 4.45 4.23 3.30 2.83 0.20 0.07 0.05
Total Noncurrent Assets		 17 16 15 12 6.70 5.67 5.18 0.00 0.40
Long-Term Investments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 17 16 15 12 6.70 5.67 5.18 0.00 0.40
Total Liabilities & Shareholders' Equity		 225 168 136 110 55 73 55 46 37
Total Liabilities		 25 33 32 34 26 46 40 28 25
Total Current Liabilities		 16 25 25 28 20 18 16 9.29 10
Accounts Payable		 3.19 4.71 5.83 8.99 7.71 8.38 6.40 4.61 3.31
Accrued Expenses		 10 17 16 16 11 8.44 8.38 3.44 6.30
Other Current Liabilities		 2.83 3.17 3.29 2.69 1.43 0.76 0.79 1.24 0.88
Total Noncurrent Liabilities		 9.27 7.93 7.05 6.88 6.50 28 24 18 14
Other Noncurrent Operating Liabilities		 9.27 7.93 7.05 6.88 6.50 28 24 18 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 200 135 104 76 29 28 16 19 12
Total Preferred & Common Equity		 200 135 104 76 29 28 16 19 12
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 200 135 104 76 29 28 16 19 12
Common Stock		 414 423 429 434 445 465 469 480 482
Retained Earnings		 -214 -288 -325 -358 -417 -437 -454 -461 -470
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Biomea Fusion

This table displays calculated financial ratios and metrics derived from Biomea Fusion's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 29,044,784.00 29,396,246.00 35,705,786.00 - 70,703,639.00
DEI Adjusted Shares Outstanding		 0.00 0.00 29,044,784.00 29,396,246.00 35,705,786.00 - 70,703,639.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.43 -2.78 -3.28 - -0.87
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -345.10% -655.74% -105.98% -50.51% -14.21% 56.26%
EBIT Growth		 0.00% -345.77% -682.19% -100.72% -50.82% -14.22% 55.82%
NOPAT Growth		 0.00% -345.77% -682.19% -100.72% -50.82% -14.22% 42.03%
Net Income Growth		 0.00% -344.41% -680.75% -96.86% -43.29% -18.06% 55.36%
EPS Growth		 0.00% -155.00% -241.18% -60.92% -22.86% -11.34% 69.19%
Operating Cash Flow Growth		 0.00% 0.00% -694.75% -76.13% -54.75% -24.12% 41.31%
Free Cash Flow Firm Growth		 0.00% 0.00% -1,018.95% -50.98% -69.32% -19.51% 61.41%
Invested Capital Growth		 0.00% 0.00% 550.93% -243.35% -64.55% 11.55% -271.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -34.16% -17.55% -9.51% 4.88% 37.78%
EBIT Q/Q Growth		 0.00% 0.00% -36.93% -16.01% -9.60% 4.79% 37.51%
NOPAT Q/Q Growth		 0.00% 0.00% -36.93% -16.01% -9.60% 4.79% 18.02%
Net Income Q/Q Growth		 0.00% 0.00% -36.94% -14.89% -8.89% 3.88% 35.43%
EPS Q/Q Growth		 0.00% 0.00% -10.13% -15.70% -2.69% 4.01% 50.42%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -59.09% -7.40% -2.81% -6.36% 18.58%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -5.67% -1.50% -8.94% 24.86%
Invested Capital Q/Q Growth		 0.00% 0.00% 1,186.86% -52.67% -5,328.10% 42.71% 16.35%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.25% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.94% 99.76% 97.84% 92.96% 96.08% 97.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -8.74% -34.68% -56.96% -84.42% -125.38% -152.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -982.30% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -0.74% -26.62% -56.96% -84.42% -125.38% -152.35%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -103.00% -23.25% -75.39% 0.00% -268.41% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.84 -3.73 -29 -59 -88 -101 -58
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -5.17% -10.46% -16.13% -19.93% -31.86% -5.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -53.94% -52.17% -195.55% -197.82%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.20 -5.33 -42 -84 -126 -144 -64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.20 -5.32 -40 -83 -125 -142 -62
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 29.60 1.21 2.28 3.06 2.73 2.97
Price to Tangible Book Value (P/TBV)		 0.00 29.60 1.21 2.28 3.06 2.73 2.97
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 12.09 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.01 -0.99 -1.01 -1.05 -1.07 -1.41
Leverage Ratio		 0.00 1.03 1.04 1.10 1.19 1.27 1.71
Compound Leverage Factor		 0.00 1.03 1.03 1.07 1.10 1.22 1.66
Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 91.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 8.48% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 11.59 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 16.54 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 57.40 18.75 4.52 7.25 -9.06 -11.55
Noncontrolling Interest Sharing Ratio		 0.00% 91.51% 23.25% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 38.43 38.08 6.17 7.84 3.15 5.23
Quick Ratio		 0.00 38.11 37.42 5.92 7.74 2.69 5.03
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2.98 -33 -50 -85 -102 -39
Operating Cash Flow to CapEx		 0.00% -8,743.14% -1,117.57% -6,059.90% -2,866.23% -33,119.89% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -0.75 3.39 -4.86 -8.00 -7.08 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.75 4.14 -8.25 -3.14 0.92 -19
Enterprise Value (EV)		 0.00 147 41 134 341 82 32
Market Capitalization		 153 153 216 248 518 141 88
Book Value per Share		 $0.00 $0.49 $6.16 $3.69 $4.74 $1.42 $0.42
Tangible Book Value per Share		 $0.00 $0.49 $6.16 $3.69 $4.74 $1.42 $0.42
Total Capital		 0.00 61 179 109 169 52 30
Total Debt		 0.00 0.04 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -62 -175 -113 -177 -59 -56
Capital Expenditures (CapEx)		 0.00 0.05 3.17 1.03 3.37 0.36 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.06 -1.59 -15 -21 -12 -8.86
Debt-free Net Working Capital (DFNWC)		 0.00 61 172 99 156 47 47
Net Working Capital (NWC)		 0.00 61 172 99 156 47 47
Net Nonoperating Expense (NNE)		 0.36 1.60 12 23 29 38 3.34
Net Nonoperating Obligations (NNO)		 0.00 -62 -175 -113 -177 -59 -56
Total Depreciation and Amortization (D&A)		 0.00 0.01 1.47 0.84 1.52 1.75 1.41
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($3.44) ($3.83) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 34.11M 36.11M 52.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($3.44) ($3.83) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 34.11M 36.11M 52.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 35.89M 37.57M 72.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.84 -3.73 -29 -59 -88 -101 -57
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Biomea Fusion

This table displays calculated financial ratios and metrics derived from Biomea Fusion's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 35,705,786.00 35,889,360.00 35,944,584.00 36,210,167.00 - 37,572,250.00 37,572,250.00 59,508,518.00 70,703,639.00 72,299,440.00 72,299,440.00
DEI Adjusted Shares Outstanding		 35,705,786.00 35,889,360.00 35,944,584.00 36,210,167.00 - 37,572,250.00 37,572,250.00 59,508,518.00 70,703,639.00 72,299,440.00 72,299,440.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.98 -1.09 -1.04 -0.91 - -0.78 -0.55 -0.28 0.07 -0.17 -0.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -41.48% -33.30% -44.73% -9.46% 19.79% 28.16% 45.34% 39.36% 60.57% 55.14% 36.56%
EBIT Growth		 -42.06% -36.72% -40.64% -9.38% 19.43% 27.64% 45.30% 38.88% 61.03% 57.01% 40.00%
NOPAT Growth		 -42.06% -36.72% -40.64% -9.38% 19.43% 27.64% 45.30% 38.88% 44.33% 57.01% 40.00%
Net Income Growth		 -37.81% -34.46% -49.76% -15.33% 16.00% 25.09% 44.36% 49.96% 115.74% 57.82% 40.64%
EPS Growth		 -10.34% -11.22% -47.14% -13.75% 16.67% 26.61% 50.49% 70.33% 150.00% 78.75% 76.47%
Operating Cash Flow Growth		 -13.05% -33.21% -26.46% -5.51% -31.38% 19.87% 41.15% 54.20% 53.53% 54.54% 47.80%
Free Cash Flow Firm Growth		 -126.71% -10.22% 20.12% 54.92% 4.42% -6.09% 125.51% 139.55% 133.97% 142.56% -454.76%
Invested Capital Growth		 -64.55% -214.51% -794.85% -8,171.24% 11.55% 24.84% -195.81% -154.21% -271.17% -251.43% 19.70%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -20.22% -7.40% 0.42% 14.87% 11.90% 3.81% 24.24% 5.55% 42.72% -9.44% 0.58%
EBIT Q/Q Growth		 -19.95% -10.00% 5.26% 12.49% 11.65% 1.20% 28.39% 2.21% 43.67% -9.00% 0.06%
NOPAT Q/Q Growth		 -19.95% -10.00% 5.26% 12.49% 11.65% 1.20% 28.39% 2.21% 19.53% 23.70% 0.06%
Net Income Q/Q Growth		 -22.71% -11.97% 4.57% 12.04% 10.63% 0.14% 29.12% 20.89% 128.11% -367.65% -0.83%
EPS Q/Q Growth		 -20.00% -13.54% 5.50% 11.65% 12.09% 0.00% 36.25% 47.06% 248.15% -142.50% 29.41%
Operating Cash Flow Q/Q Growth		 4.44% -40.25% -1.91% 22.75% -18.98% 14.45% 25.15% 39.88% -20.71% 16.30% 14.06%
Free Cash Flow Firm Q/Q Growth		 8.47% 4.58% 26.50% 29.76% -94.04% -5.91% 117.67% 8.89% 66.67% 32.67% -247.34%
Invested Capital Q/Q Growth		 -5,328.10% -24.68% 2.67% -27.22% 42.71% -5.95% -283.06% -9.33% 16.35% -0.32% 12.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.45% 95.13% 95.83% 96.32% 97.43% 98.49% 97.48% 78.86% -39.35% 96.63% 97.50%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -84.42% -116.52% -85.09% -104.51% -125.38% -156.81% -170.54% -209.00% -152.35% -189.14% -183.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -84.42% -116.52% -85.09% -104.51% -125.38% -156.81% -170.54% -209.00% -152.35% -189.14% -183.41%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -94.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -29 -27 -24 -21 -21 -15 -15 -12 -8.94 -8.94
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.02% -8.91% -5.97% -6.23% -7.00% -9.33% -6.88% -2.72% 28.54% -8.37% -7.68%
Return On Investment Capital (ROIC_SIMPLE)		 -15.44% -21.24% -26.19% -31.36% -40.82% -72.38% -54.14% -93.24% -39.66% -47.77% -73.63%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -37 -41 -39 -34 -30 -30 -21 -21 -12 -13 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 -40 -39 -34 -30 -28 -22 -20 -12 -13 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.06 3.97 1.56 4.81 2.73 2.78 2.46 7.70 2.97 5.91 8.76
Price to Tangible Book Value (P/TBV)		 3.06 3.97 1.56 4.81 2.73 2.78 2.46 7.70 2.97 5.91 8.76
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.06 -1.03 -1.04 -1.07 -1.11 -1.29 -1.48 -1.41 -1.71 -2.31
Leverage Ratio		 1.19 1.29 1.17 1.22 1.27 1.36 1.59 1.81 1.71 2.14 2.78
Compound Leverage Factor		 1.11 1.22 1.12 1.17 1.23 1.34 1.55 1.43 -0.67 2.07 2.71
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.72 7.38 -0.47 1.53 -4.35 -10.01 -7.67 -10.19 -8.62 -11.48 -15.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.84 5.84 4.62 3.39 3.15 2.25 3.68 3.18 5.23 4.98 3.48
Quick Ratio		 7.74 5.74 4.50 3.19 2.69 1.81 3.20 3.00 5.03 4.81 3.32
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -22 -16 -11 -22 -23 4.11 4.48 7.47 9.91 -15
Operating Cash Flow to CapEx		 -285,462.50% -91,514.29% -55,327.12% -13,557.53% -36,590.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.00 -9.97 -9.71 -12 -7.08 -7.50 -29 -31 -26 -26 -23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.14 -6.80 -11 -13 0.92 2.48 -19 -19 -19 -19 5.66
Enterprise Value (EV)		 341 391 48 277 82 44 11 73 32 66 71
Market Capitalization		 518 537 162 366 141 80 68 120 88 111 106
Book Value per Share		 $4.74 $3.77 $2.89 $2.10 $1.42 $0.79 $0.73 $0.26 $0.42 $0.26 $0.17
Tangible Book Value per Share		 $4.74 $3.77 $2.89 $2.10 $1.42 $0.79 $0.73 $0.26 $0.42 $0.26 $0.17
Total Capital		 169 135 104 76 52 29 28 16 30 19 12
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -177 -145 -114 -88 -59 -36 -56 -47 -56 -45 -35
Capital Expenditures (CapEx)		 0.01 0.04 0.06 0.19 0.08 0.00 0.00 0.00 0.00 -0.55 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -23 -23 -22 -12 -11 -9.13 -13 -8.86 -8.04 -9.25
Debt-free Net Working Capital (DFNWC)		 156 122 91 66 47 25 47 34 47 37 26
Net Working Capital (NWC)		 156 122 91 66 47 25 47 34 47 37 26
Net Nonoperating Expense (NNE)		 8.75 10 10 8.96 8.25 8.46 5.85 1.84 -16 3.40 3.51
Net Nonoperating Obligations (NNO)		 -177 -145 -114 -88 -59 -36 -56 -47 -56 -45 -35
Total Depreciation and Amortization (D&A)		 0.42 1.42 -0.58 0.44 0.47 1.23 -0.30 0.43 0.05 0.00 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding		 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M 72.36M
Adjusted Diluted Earnings per Share		 ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding		 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M 72.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.89M 35.94M 36.21M 36.24M 37.57M 37.57M 59.51M 70.70M 72.30M 72.30M 72.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -29 -27 -24 -21 -21 -15 -13 -8.20 -8.94 -8.94
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Biomea Fusion remains a development-stage biotechnology company with no reported revenue across the periods provided. Its financial profile is improving in some respects, but the company continues to fund operations primarily through its cash balance and equity financing rather than commercial sales.

Operating expenses have declined materially. Total operating expenses fell from $41.1 million in Q1 2024 to $12.8 million in Q2 2026. Research and development spending declined from $33.8 million to $9.1 million over the same period, while selling, general and administrative expense decreased from $7.3 million to $3.6 million. The quarterly net loss also narrowed from $39.1 million in Q1 2024 to $12.4 million in Q2 2026.

Cash usage has improved alongside the lower expense base. Net cash used in operating activities declined from $32.0 million in Q1 2024 to $10.0 million in Q2 2026. However, Biomea’s cash balance has fallen sharply over the longer term, from $199.1 million in Q3 2023 to $34.8 million as of June 30, 2026, excluding $369,000 of restricted cash.

  • Lower operating expenses: Quarterly operating expenses have been reduced by approximately 69% from Q1 2024 to Q2 2026, which could extend the company’s cash runway if spending remains controlled.
  • Improving operating cash burn: Cash used in operating activities declined to $10.0 million in Q2 2026 from $11.7 million in Q1 2026 and $32.0 million in Q1 2024.
  • Stronger short-term liquidity: Q2 2026 current assets of $36.4 million exceeded current liabilities of $10.5 million, producing a current ratio of roughly 3.5.
  • Lower near-term liabilities: Total liabilities declined to $24.7 million in Q2 2026 from $45.7 million in Q2 2024, while current liabilities fell to $10.5 million from $25.2 million over the same period.
  • Interest income provides modest support: Interest and investment income contributed $319,000 in Q2 2026, but this remains small relative to the company’s quarterly operating loss.
  • Limited capital investment: Net property, plant and equipment was only $47,000 at June 30, 2026, indicating that Biomea’s cash needs are primarily tied to research, development and corporate expenses rather than heavy infrastructure spending.
  • No commercial revenue: Revenue was reported at zero in each of the supplied income-statement periods, leaving Biomea dependent on cash reserves, financing and potential future product development success.
  • Substantial cumulative losses: Retained earnings were negative $469.8 million at the end of Q2 2026, compared with negative $287.9 million in Q1 2024, reflecting significant accumulated losses.
  • Cash reserves have been depleted: Cash and equivalents fell approximately 82% from $199.1 million in Q3 2023 to $34.8 million in Q2 2026. At the Q2 operating cash-burn rate, the cash balance provides only a limited number of quarters of funding before additional financing may be needed.
  • Meaningful dilution risk: Weighted-average basic shares outstanding increased from 35.9 million in Q1 2024 to 72.4 million in Q2 2026. Continued equity issuance could provide liquidity but may reduce existing shareholders’ ownership percentage.

Overall, Biomea’s cost structure and quarterly cash burn are moving in a favorable direction, but the company has not yet generated revenue and its balance-sheet resources have contracted significantly. The key financial issue for investors is whether the reduced spending rate can preserve liquidity long enough for Biomea to reach meaningful clinical or commercial milestones without substantial additional equity financing.

10/15/26 11:51 AM ETAI Generated. May Contain Errors.

Biomea Fusion Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Biomea Fusion's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Biomea Fusion's net income appears to be on a downward trend, with a most recent value of -$61.80 million in 2025, falling from -$1.20 million in 2019. The previous period was -$138.43 million in 2024. Check out Biomea Fusion's forecast to explore projected trends and price targets.

Biomea Fusion's total operating income in 2025 was -$83.51 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $83.51 million

Over the last 6 years, Biomea Fusion's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

In the past 11 quarters, Biomea Fusion's cash and equivalents has ranged from $34.82 million in Q2 2026 to $199.09 million in Q3 2023, and is currently $34.82 million as of their latest financial filing in Q2 2026.

Biomea Fusion had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, Biomea Fusion's book value per share changed from 0.00 in 2019 to 0.42 in 2025, a change of 41.8%.


Related Companies

Financial statements for NASDAQ:BMEA last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel